{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:04:17Z","timestamp":1781071457395,"version":"3.54.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, they can trigger diverse immune-related adverse events (irAEs). Among these, ICI-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome (ICI-MMM) is a rare but potentially fatal complication. Conventional immunotherapy often exhibits limited efficacy against ICI-MMM, which is associated with high mortality rates. Thus, there is an urgent need for novel and effective strategies to mitigate its life-threatening outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of the successful rescue use of eculizumab in a patient with tislelizumab-related MMM overlap syndrome who tested seropositive for both anti-acetylcholine receptor (AChR) and anti-titin antibodies. We also performed a focused systematic literature review on the use of complement inhibitor therapy for ICI-related myasthenia gravis and its overlap syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>A 64-year-old male developed ptosis and tetraparesis two weeks following the second infusion of tislelizumab for lung adenocarcinoma. Serological testing revealed dual positivity for anti-AChR antibody and anti-titin antibody. Tislelizumab was immediately withdrawn, and the patient was treated with corticosteroids and intravenous immunoglobulin as first-line therapy. However, his clinical condition deteriorated rapidly, and new symptoms emerged, including chest pain, muscle pain, dysphagia, slurred speech, and dyspnea. Although the absence of histopathological confirmation for myocarditis and myositis, the clinical, laboratory, electrophysiological, and cardiac imaging findings supported the diagnosis of probable ICI-MMM. Rescue therapy with eculizumab was commenced (900 mg weekly for four doses), eliciting rapid and marked clinical improvement. The patient ultimately achieved minimal symptom expression without any exacerbation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first reported case of successful eculizumab rescue treatment for probable tislelizumab-related MMM overlap syndrome with dual seropositivity. Our finding suggests eculizumab may represent a promising rescue option for ICI-MMM warranting prospective evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1873528","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:41:30Z","timestamp":1781070090000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful rescue therapy with eculizumab for probable tislelizumab-related MMM overlap syndrome with dual positivity for anti-acetylcholine receptor and anti-titin antibodies: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Yi-Xiao","family":"Li","sequence":"first","affiliation":[{"name":"Department of Neurology, Ningbo Taikang Hospital","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Lei","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ningbo Taikang Hospital","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Hossain","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1597259","article-title":"Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review","volume":"16","author":"S\u00e1nchez-Camacho","year":"2025","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00520-023-07987-x","article-title":"Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series","volume":"31","author":"Weaver","year":"2023","journal-title":"Supp Care Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000008688","article-title":"Myasthenic crisis demanding mechanical ventilation: A multicenter analysis of 250 cases","volume":"94","author":"Neumann","year":"2020","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-07190-0","article-title":"Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors","volume":"45","author":"Fionda","year":"2024","journal-title":"Neurol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200177","article-title":"Immune checkpoint inhibition-related myasthenia-myositis-myocarditis responsive to complement blockade","volume":"11","author":"Nelke","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28037","article-title":"Novel uses of complement inhibitors in myasthenia gravis-two case reports","volume":"69","author":"Zadeh","year":"2024","journal-title":"Muscle Nerve"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251333518","article-title":"Eculizumab as fast-acting rescue therapy for pembrolizumab-induced impending crisis state of myasthenia gravis: a case report","volume":"18","author":"Huang","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1199031","article-title":"Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2024.100111","article-title":"Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: multicenter study using natural language processing on Belgian hospital data","volume":"7","author":"Delombaerde","year":"2025","journal-title":"ESMO Real World Data Dig Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10020304","article-title":"The diagnosis and management of immune checkpoint inhibitor cardiovascular toxicity: Myocarditis and beyond","volume":"10","author":"Gilon","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14161794","article-title":"Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review","volume":"14","author":"Lipe","year":"2024","journal-title":"Diagnost (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100772","article-title":"Myasthenia gravis in patients treated with immune checkpoint inhibitors","volume":"6","author":"Alghabban","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310919","article-title":"Pembrolizumab-induced fatal myasthenia, myocarditis, and myositis in a patient with metastatic melanoma: Autopsy, histological, and immunohistochemical findings-a case report and literature review","volume":"24","author":"Giovannini","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000196","article-title":"PD-1 inhibitor-associated myopathies: Emerging immune-mediated myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J Immunother"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1956-18","article-title":"Pembrolizumab-induced ocular myasthenia gravis with anti-titin antibody and necrotizing myopathy","volume":"58","author":"Onda","year":"2019","journal-title":"Intern Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1423547","article-title":"Case report: Multi-antibody-positive myasthenia gravis concomitant myositis associated with thymoma","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213777","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132063","article-title":"Management of triple M syndrome: A narrative review of immune checkpoint inhibitor-induced myasthenia gravis, myositis and myocarditis","volume":"17","author":"Furlepa","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.978997","article-title":"Anti-titin antibody is associated with more frequent hospitalization to manage thymoma-associated myasthenia gravis","volume":"13","author":"Kim","year":"2022","journal-title":"Front Neurol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577767","article-title":"Eculizumab treatment for myasthenia gravis subgroups: 2021 update","volume":"362","author":"Jiao","year":"2022","journal-title":"J Neuroimmunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0000000000001727","article-title":"Nivolumab- and ipilimumab-induced myositis, myasthenia gravis, and myocarditis in a patient with metastatic melanoma","volume":"36","author":"Inan","year":"2025","journal-title":"Anticancer Drugs"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1873528\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:41:33Z","timestamp":1781070093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1873528\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1873528"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1873528","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1873528"}}